Notice2021-14637
Requests for Proposals for Insulin Reimportation and Personal Prescription Drug Importation; Withdrawal
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
July 9, 2021
Issuing agencies
Health and Human Services DepartmentFood and Drug Administration
Abstract
The Department of Health and Human Services (Department or HHS) is announcing the withdrawal of a notice published in the Federal Register on January 21, 2021, entitled "Requests for Proposals for Insulin Reimportation and Personal Prescription Drug Importation." HHS also withdraws the requests for proposals issued on its website on September 24, 2020, and revised on January 13, 2021, and ends the period for submission of proposals in response to the requests for proposals.
Full Text
<html>
<head>
<title>Federal Register, Volume 86 Issue 129 (Friday, July 9, 2021)</title>
</head>
<body><pre>
[Federal Register Volume 86, Number 129 (Friday, July 9, 2021)]
[Notices]
[Pages 36283-36284]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2021-14637]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2021-Z-0025]
Requests for Proposals for Insulin Reimportation and Personal
Prescription Drug Importation; Withdrawal
AGENCY: Food and Drug Administration (FDA), Department of Health and
Human Services (HHS).
ACTION: Notice; withdrawal.
-----------------------------------------------------------------------
SUMMARY: The Department of Health and Human Services (Department or
HHS) is announcing the withdrawal of a notice published in the Federal
Register on January 21, 2021, entitled ``Requests for Proposals for
Insulin Reimportation and Personal Prescription Drug Importation.'' HHS
also withdraws the requests for proposals issued on its website on
September 24, 2020, and revised on January 13, 2021, and ends the
period for submission of proposals in response to the requests for
proposals.
DATES: The notice published in the Federal Register on January 21,
2021, at 86 FR 6343, is withdrawn as of July 9, 2021.
FOR FURTHER INFORMATION CONTACT: Katelyn Mineo, Center for Drug
Evaluation and Research, Food and Drug Administration, 10903 New
Hampshire Ave., Bldg. 51, Rm. 6222, Silver Spring, MD 20993, 301-796-
1054.
SUPPLEMENTARY INFORMATION: On September 24, 2020, HHS issued two
requests for proposals for the reimportation of insulin and the
personal importation of prescription drugs (collectively, the RFPs) and
posted related ``Frequently Asked Questions'' documents (FAQs) on its
website. On January 21, 2021, HHS published a notice in the Federal
Register entitled ``Requests for Proposals for Insulin Reimportation
and Personal Prescription Drug Importation'' (the HHS Notice) (86 FR
6343). The HHS Notice referred to revised versions
[[Page 36284]]
of the RFPs. The responses to the RFPs were directed in the HHS Notice
and in the RFP for Personal Prescription Drug Importation issued on
September 24, 2020, and revised on January 13, 2021, to be submitted to
an HHS email address: <a href="/cdn-cgi/l/email-protection#ddb4b0adb2afa99db5b5aef3bab2ab"><span class="__cf_email__" data-cfemail="e28b8f928d9096a28a8a91cc858d94">[email protected]</span></a>, while the RFP for Insulin
Reimportation Programs issued on September 24, 2020, and revised on
January 13, 2021, directed that responses be sent to <a href="/cdn-cgi/l/email-protection#01686c716e7375416969722f666e77"><span class="__cf_email__" data-cfemail="543d39243b2620143c3c277a333b22">[email protected]</span></a> and
to the Director of the FDA Import Division in the region of the
intended port of entry. The Department is not aware that any proposals
were received in response to the HHS Notice or RFPs. The HHS Notice,
RFPs, and FAQs are withdrawn. All website statements and other informal
issuances with respect to the HHS Notice and RFPs are also withdrawn.
Accordingly, no proposals submitted to HHS or FDA in response to the
HHS Notice or RFPs on or after July 9, 2021 will be considered by HHS
or FDA. HHS intends to consider alternatives to the RFPs.
Dated: June 11, 2021.
Janet Woodcock,
Acting Commissioner of Food and Drugs.
Dated: June 28, 2021.
Xavier Becerra,
Secretary, Department of Health and Human Services.
[FR Doc. 2021-14637 Filed 7-8-21; 8:45 am]
BILLING CODE 4164-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on July 9, 2021.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.